BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/20/2023 7:26:29 AM | Browse: 362 | Download: 1253
 |
Received |
|
2022-09-19 00:10 |
|
Peer-Review Started |
|
2022-09-19 00:12 |
|
First Decision by Editorial Office Director |
|
2022-12-01 04:02 |
|
Return for Revision |
|
2022-12-01 04:53 |
|
Revised |
|
2022-12-20 06:34 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-03-24 02:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-03-24 06:27 |
|
Articles in Press |
|
2023-03-24 06:27 |
|
Edit the Manuscript by Language Editor |
|
2023-03-16 02:57 |
|
Typeset the Manuscript |
|
2023-03-27 09:33 |
|
Publish the Manuscript Online |
|
2023-04-20 07:26 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Recent advances in recurrent hepatocellular carcinoma therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, Tong-Wang Yang and De-Xi Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82073676 |
| Chinesisch-Deutsches Forschungsprojekt in Sonderprogramm zu COVID-19 |
C-0012 |
| Key Programs of Beijing Municipal Education Commission of China |
KZ202010025037 |
| Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes |
Jing 2019-6 |
| Fourth Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes |
Jing 2021-10 |
|
| Corresponding Author |
De-Xi Chen, PhD, Professor, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, No. 8 Youanmenwai, Youanmen Street, Fengtai District, Beijing 100069, China. dexichen@ccmu.edu.cn |
| Key Words |
Recurrent hepatocellular carcinoma; Liver transplantation; Therapy; Immunotherapy; Neoadjuvant and adjuvant therapy |
| Core Tip |
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, and up to 50%-70% of individuals may experience a relapse of the illness in the liver after 5 years. This review will provide novel approaches to improve the prognosis of patients with recurring HCC with the apparent lack of data to guide the clinical treatment. Neoadjuvant and/or adjuvant therapy methods potentially elevate the opportunity of cure in refractory patients with recurrent HCC and contribute to a better long-term prognosis. |
| Publish Date |
2023-04-20 07:26 |
| Citation |
Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent hepatocellular carcinoma therapy. World J Hepatol 2023; 15(4): 460-476 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i4/460.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i4.460 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
